READING,
Pa., June 19, 2024 /PRNewswire/
-- PharmaForce International (PFI) publishes a yearly
competitive intelligence report benchmarking the commercial
operations of leading Immunology sales and marketing organizations
in the United States. The report
focuses on key companies with products competing across
Dermatology, Gastroenterology, Rheumatology, and Respiratory areas.
The latest edition of this report was published in November 2023 and contains many noteworthy
findings. Among these findings are the various strategic responses
to the Immunology biosimilars that were launched in 2023.
Since the previous edition of the United States Immunology
report, there were many new biosimilar approvals and launches,
causing a highly competitive market in 2023. PFI observed and
captured the various strategies adapted by companies promoting
these approved biosimilars in response to the competitive
pressure.
One strategy, in particular, included employing contract sales
forces to promote the biosimilar products as a way to test the
waters before making a long-term investment. On the other hand,
some companies opted to not deploy a sales force for their
biosimilars, and instead adopted a strategy of utilizing online
pharmacies.
Allison Keylor, Director of the
U.S. Syndicated Business Unit at PFI, states "These biosimilars do
not have the assistance programs or managed care wins that branded
products offer to withhold current and future patients on therapy.
Companies promoting the newly approved Immunology biosimilars had
to get creative with their selling strategies in 2023."
Many more competitive responses and strategies to the
ever-changing market are captured within the 2023 United States
Immunology benchmarking report. In addition to the United States, the Immunology benchmarking
study has also been conducted in Europe. The EU5 report was published in
December 2023. The 2024 updates for
both the US and Europe Immunology reports are anticipated to be
published in Q4 2024.
For more information on the report mentioned above, please
contact Joyce Wedemeyer at
Joyce.Wedemeyer@pharmaforceintl.com or by phone at
610-370-2906.
PharmaForce International (PFI), an SAI MedPartners LLC
division, is a competitive intelligence firm with over two decades
of experience in the pharmaceutical and biotech industries. PFI has
become the market leader in commercial operations benchmarking and
competitive intelligence.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pharmaforce-international-benchmarking-report-captures-key-us-immunology-companies-strategic-responses-to-the-2023-biosimilar-approvals-302177170.html
SOURCE PharmaForce International